| 2.95 -0.2 (-6.35%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.77 | 1-year : | 4.4 |
| Resists | First : | 3.23 | Second : | 3.77 |
| Pivot price | 2.94 |
|||
| Supports | First : | 2.7 | Second : | 2.38 |
| MAs | MA(5) : | 2.98 |
MA(20) : | 2.89 |
| MA(100) : | 2.44 |
MA(250) : | 0 | |
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 63.6 |
D(3) : | 60.8 |
| RSI | RSI(14): 56.2 |
|||
| 52-week | High : | 3.23 | Low : | 1.82 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ORMP ] has closed below upper band by 49.3%. Bollinger Bands are 55% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 25 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.17 - 3.18 | 3.18 - 3.2 |
| Low: | 2.89 - 2.91 | 2.91 - 2.93 |
| Close: | 2.92 - 2.95 | 2.95 - 2.98 |
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Wed, 24 Dec 2025
Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback - Seeking Alpha
Fri, 21 Nov 2025
Oramed Pharmaceuticals' (NASDAQ:ORMP) Profits May Be Overstating Its True Earnings Potential - simplywall.st
Mon, 17 Nov 2025
Oramed Reports Fiscal Third Quarter 2025 Financial Results - PR Newswire
Mon, 17 Nov 2025
Oramed (ORMP) Implements Stockholder Rights Agreement - GuruFocus
Mon, 17 Nov 2025
ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS - PR Newswire
Fri, 24 Oct 2025
Oramed Pharmaceuticals repurchases shares and ends joint venture with HTIT - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 3.135e+007 (%) |
| Held by Institutions | 13.5 (%) |
| Shares Short | 242 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.289e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 2 % |
| Operating Margin | 192.6 % |
| Return on Assets (ttm) | -650.6 % |
| Return on Equity (ttm) | -4.3 % |
| Qtrly Rev. Growth | 2e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 20.92 |
| EBITDA (p.s.) | 11111.1 |
| Qtrly Earnings Growth | 1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.14 |
| Price to Cash Flow | 0.69 |
| Dividend | 0 |
| Forward Dividend | 357420 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|